公开(公告)号：US20230312602A1

公开(公告)日：2023-10-05

申请号：US18296215

申请日：2023-04-05

Applicant: AMGEN INC.

Inventor： Henry Morrison ,  Jason S. Tedrow ,  Stephan D. Parent ,  Courtney Johnson ,  Travis Houston ,  Melanie Bevill

IPC: C07D513/08

CPC classification number: C07D513/08 ,  C07B2200/13

Abstract: Disclosed herein are salt and solvate forms of. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-methoxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (AMG 176):




such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.

公开(公告)号：US12252486B2

公开(公告)日：2025-03-18

申请号：US17612717

申请日：2020-05-20

Applicant: Amgen Inc.

Inventor： Mary Chaves ,  Ron C. Kelly ,  Prashant Agarwal ,  Stephan D. Parent ,  Darren Leonard Reid ,  Roman Shimanovich

IPC: C07D471/04 ,  A61P35/00

Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.